3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Observational
2
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
CNS
1
Conditions
Breast Neoplasms
91
Neoplasm Metastasis
24
Neoplasms
14
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Oligodendroglioma
2
Interventions
exemestane
7
Trastuzumab
7
Anastrozole
7
Letrozole
6
Docetaxel
6
palbociclib
5
pyrotinib
4
entinostat
4
Fulvestrant
4
Cyclophosphamide
4
ribociclib
3
abemaciclib
3
Tamoxifen
3
Doxorubicin
3
pertuzumab
2
Sodium Chloride
2
Paclitaxel
2
Lapatinib
2
Gonadotropin-Releasing Hormone
2
Exercise
2
Everolimus
2
Epirubicin
2
Drug Evaluation
2
Capecitabine
2
Botulinum Toxins, Type A
2
Aromatase Inhibitors
2
AZD9833
2
trastuzumab deruxtecan
1
taxane
1
sacubitril and valsartan sodium hydrate drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Breast Diseases
×
abemaciclib
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT05386108
2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled